The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
-
Heart Center Research LLC, Huntsville, Alabama, United States, 35801
Mobile Heart Specialists PC, Mobile, Alabama, United States, 36608
Velocity Clinical Research- Los Angeles, Los Angeles, California, United States, 90017
Velocity Clinical Research - Boise, Meridian, Idaho, United States, 83642
MD Medical Research, Oxon Hill, Maryland, United States, 20745
Velocity Clinical Research - Binghamton, Binghamton, New York, United States, 13905
Velocity Clinical Research - Cleveland, Beachwood, Ohio, United States, 44122
Velocity Clinical Research - Auburn, Cincinnati, Ohio, United States, 45219
Heritage Valley Multispecialty Group Inc, Beaver, Pennsylvania, United States, 15009
Velocity Clinical Research - Providence, East Greenwich, Rhode Island, United States, 02818
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
45 Years to 99 Years
ALL
No
Amgen,
MD, STUDY_DIRECTOR, Amgen
2030-09-29